Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome - 12/08/11
Chicago, Illinois, and Boston, Massachusetts
Abstract |
We conducted a phase II trial to evaluate the efficacy and toxicity of subcutaneous injections of recombinant interleukin (IL)-2 in 22 heavily pretreated patients with advanced cutaneous T-cell lymphoma. We observed modest response rates (18%) with a reasonable toxicity profile. The role of IL-2 in vivo for expansion of cytotoxic CD8+ T cells, CD4+ T cells, regulatory CD25+ T cells, or a combination of these has not been elucidated. There was no evidence of expansion of CD8+ T cells in peripheral blood of patients during treatment. Immunophenotypic analysis revealed an increase of CD25+ cells in CD3+ and CD4+ populations after treatment in a subset of patients possibly reflecting activation of reactive helper T cells, proliferation of neoplastic T cells, or proliferation of T-regulatory cells. In summary, at this dose and schedule recombinant IL-2 is largely ineffective as therapy in patients with advanced cutaneous T-cell lymphoma. Whether IL-2 has the potential to suppress antitumor activity by stimulation of regulatory T cells needs to be clarified.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CTCL, ECOG, IL, MF, rIL-2, SS, Treg
Plan
Supported in part by Chiron Pharmaceuticals. Conflicts of interest: None identified. |
Vol 56 - N° 4
P. 580-583 - avril 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?